80 related articles for article (PubMed ID: 18162894)
1. Completion angiography for surgically treated cerebral aneurysms: an economic analysis.
Stein SC; Burnett MG; Zager EL; Riina HA; Sonnad SS
Neurosurgery; 2007 Dec; 61(6):1162-7; discussion 1167-9. PubMed ID: 18162894
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of preventive treatment of intracranial aneurysms: new data and uncertainties.
Greving JP; Rinkel GJ; Buskens E; Algra A
Neurology; 2009 Jul; 73(4):258-65. PubMed ID: 19299311
[TBL] [Abstract][Full Text] [Related]
3. Cost-effective screening for cerebral aneurysms.
Alterman RL; Drucker E
Neurosurg Clin N Am; 1998 Jul; 9(3):497-507. PubMed ID: 9668182
[TBL] [Abstract][Full Text] [Related]
4. The effect of coiling versus clipping of ruptured and unruptured cerebral aneurysms on length of stay, hospital cost, hospital reimbursement, and surgeon reimbursement at the university of Florida.
Hoh BL; Chi YY; Dermott MA; Lipori PJ; Lewis SB
Neurosurgery; 2009 Apr; 64(4):614-9; discussion 619-21. PubMed ID: 19197221
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms.
Kallmes DF; Kallmes MH
AJNR Am J Neuroradiol; 1997 Sep; 18(8):1453-62. PubMed ID: 9296186
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of treatment of unruptured intracranial aneurysms in patients with a history of subarachnoid hemorrhage.
Takao H; Nojo T; Ohtomo K
Acad Radiol; 2008 Sep; 15(9):1126-32. PubMed ID: 18692753
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and costs of screening for aneurysms every 5 years after subarachnoid hemorrhage.
Wermer MJ; Koffijberg H; van der Schaaf IC;
Neurology; 2008 May; 70(22):2053-62. PubMed ID: 18420481
[TBL] [Abstract][Full Text] [Related]
8. Asymptomatic pancreatic cystic neoplasm: a cost-effectiveness analysis of different strategies of management.
Das A; Ngamruengphong S; Nagendra S; Chak A
Gastrointest Endosc; 2009 Oct; 70(4):690-699.e6. PubMed ID: 19647240
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
[TBL] [Abstract][Full Text] [Related]
10. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness analysis on different surgical strategies for intracranial aneurysms.
Gaetani P; Rodriguez y Baena R; Klersy C; Adinolfi D; Infuso L
J Neurosurg Sci; 1998 Jun; 42(2):69-78. PubMed ID: 9826790
[TBL] [Abstract][Full Text] [Related]
12. Routine angiography after surgery for ruptured intracranial aneurysms: a cost versus benefit analysis.
Kallmes DF; Kallmes MH; Lanzino G; Kassell NF; Jensen ME; Helm GA
Neurosurgery; 1997 Sep; 41(3):629-39; discussion 639-41. PubMed ID: 9310981
[TBL] [Abstract][Full Text] [Related]
13. Screening for familial intracranial aneurysms: decision and cost-effectiveness analysis.
Takao H; Nojo T; Ohtomo K
Acad Radiol; 2008 Apr; 15(4):462-71. PubMed ID: 18342771
[TBL] [Abstract][Full Text] [Related]
14. Surgical strategies using cerebral revascularization in complex middle cerebral artery aneurysms.
Seo BR; Kim TS; Joo SP; Lee JM; Jang JW; Lee JK; Kim JH; Kim SH
Clin Neurol Neurosurg; 2009 Oct; 111(8):670-5. PubMed ID: 19595503
[TBL] [Abstract][Full Text] [Related]
15. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
16. Surgical treatment of giant intracranial aneurysms: current viewpoint.
Cantore G; Santoro A; Guidetti G; Delfinis CP; Colonnese C; Passacantilli E
Neurosurgery; 2008 Oct; 63(4 Suppl 2):279-89; discussion 289-90. PubMed ID: 18981833
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
Oba Y
Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
[TBL] [Abstract][Full Text] [Related]
20. Treatment of unruptured intracranial aneurysms: decision and cost-effectiveness analysis.
Takao H; Nojo T
Radiology; 2007 Sep; 244(3):755-66. PubMed ID: 17652191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
